Fennec Pharmaceuticals Book Value 2011-2026 | FENC

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Fennec Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
35.5 M	-5.87 M	-11.6 M	-2.57 M	15.8 M	29.1 M	11.9 M	21.3 M	26.8 M	3.57 M	548 K	613 K	-1.46 M	-4.96 M	-120 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
35.5 M	-11.6 M	7.89 M

Quarterly Book Value Fennec Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-4.49 M	-7.46 M	-5.88 M	-5.87 M	-5.17 M	-1.36 M	3.01 M	-11.6 M	-10.5 M	-9.73 M	-7.34 M	-2.57 M	2.8 M	8.54 M	12.5 M	15.8 M	19 M	22.3 M	27.8 M	29.1 M	29.1 M	29.1 M	10.4 M	11.9 M	14.1 M	14.1 M	14.1 M	21.3 M	20.9 M	22.1 M	21.8 M	26.8 M	8.24 M	26.8 M	26.8 M	3.57 M	3.57 M	3.57 M	3.57 M	548 K	548 K	548 K	548 K	613 K	613 K	613 K	613 K	-1.46 M	-1.46 M	-1.46 M	-1.46 M	-4.96 M	-4.96 M	-4.96 M	-4.96 M	-120 K	-120 K	-120 K	-120 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
29.1 M	-11.6 M	6.09 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
BioLineRx Ltd. BLRX	13.5 M	$ 2.25	1.81 %	$ 908 M	Israel
BioNTech SE BNTX	19.2 B	$ 91.28	0.11 %	$ 27.2 B	Germany
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Alnylam Pharmaceuticals ALNY	789 M	$ 330.34	3.6 %	$ 43.3 B	USA
CollPlant Biotechnologies Ltd. CLGN	13.5 M	$ 0.44	-16.64 %	$ 5.04 M	Israel
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Catalyst Pharmaceuticals CPRX	954 M	$ 24.98	1.17 %	$ 3.05 B	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Corbus Pharmaceuticals Holdings CRBP	148 M	$ 10.14	-0.29 %	$ 135 M	USA
Cardiff Oncology CRDF	45.4 M	$ 1.58	-	$ 106 M	USA
Curis CRIS	5.46 M	$ 0.53	-3.07 %	$ 6.98 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Crinetics Pharmaceuticals CRNX	992 M	$ 37.7	1.26 %	$ 3.55 B	USA
CRISPR Therapeutics AG CRSP	1.92 B	$ 49.15	-0.73 %	$ 4.42 B	Schweiz
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Anavex Life Sciences Corp. AVXL	94.9 M	$ 2.96	-1.0 %	$ 252 M	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
CytomX Therapeutics CTMX	99 M	$ 4.4	-3.51 %	$ 607 M	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Citius Pharmaceuticals CTXR	74.1 M	$ 0.86	0.67 %	$ 5.79 M	USA
Cue Biopharma CUE	26.4 M	$ 0.18	-1.61 %	$ 17.1 M	USA
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	16.9 M	-	10.36 %	$ 9.8 M	USA
Aquestive Therapeutics AQST	-33.7 M	$ 4.09	-0.97 %	$ 437 M	USA
Cyclerion Therapeutics CYCN	9.58 M	$ 4.15	-32.52 %	$ 10.4 M	USA
Daré Bioscience DARE	2.84 M	$ 1.81	4.02 %	$ 20.2 M	USA
DBV Technologies S.A. DBVT	169 M	$ 20.36	-3.32 %	$ 2.84 B	France
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Arcturus Therapeutics Holdings ARCT	214 M	$ 8.22	2.37 %	$ 225 M	Israel
Aptose Biosciences APTO	-27.2 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Denali Therapeutics DNLI	1.23 B	$ 19.38	-6.15 %	$ 3.19 B	USA
Dyadic International DYAI	1.23 M	$ 0.87	-2.8 %	$ 31.5 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
AstraZeneca PLC AZN	48.7 B	-	-	$ 96.9 B	Britain
Celldex Therapeutics CLDX	527 M	$ 31.37	1.0 %	$ 2.08 B	USA
Avenue Therapeutics ATXI	1.83 M	-	-52.27 %	$ 4.45 M	USA